New Delhi, Feb 24 (PTI) Biocon Biologics on Monday said it has launched a biosimilar product to treat certain autoimmune diseases, in the US market.

YESINTEK (ustekinumab-kfce), which is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, is now available to patients in the US, the company said in a statement.

Also Read | News Headlines for School Assembly Today, 25 February 2025: Check Important National, International, Sports, Entertainment and Business Stories" is locked News Headlines for School Assembly Today, 22 February 2025: Check Important National, International, Sports, Entertainment and Business Stories.

The company's product is biosimilar to Stelara.

"The launch of YESINTEK marks a significant step in our commitment to improving the lives of patients with inflammatory conditions and expanding access to high-quality biosimilars," Biocon Biologics CEO & MD Shreehas Tambe said.

Also Read | What Is Online Insurance Scam? Know How To Stay Safe as Mumbai Woman Loses INR 1 Lakh to Fraudster Posing As SBI Life Official.

Biocon Biologics Inc Head of North America Josh Salsi said:"For healthcare providers, switching to YESINTEK offers a seamless treatment experience covering the same indications and dosing options."

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)